title: [Clinical variants of chronic urticaria associated with Helicobacter pylori].
abstract: BACKGROUND
  Chronic urticaria (CU) is one of the toughest problems. The main difficulty is the search for an etiological factor in 70-90% of cases the cause of chronic urticaria remains unclear. In the development and persistence of CU recently paid great importance to the role of Helicobacter pylori infection (HP), which is the most common bacterial infection in humans. However, the influence of HP eradication on the course of CU is poorly understood.
  
  
  OBJECTIVE
  to improve the diagnosis and treatment of urticaria patients with Helicobacter-associated diseases of the upper gastrointestinal tract.
  
  
  METHODS
  The study included 184 patients with clinical manifestations of urticaria and HP-associated gastroduodenal pathology in the age of 18.
  
  
  RESULTS
  Infection with HP was more frequently detected in patients with chronic idiopathic urticaria in comparison with patients with allergic urticaria (73% and 56% respectively, p < 0.05). In patients with allergic and chronic idiopathic urticaria HP-associating chronic gastritis were detected respectively in 90% and 81% of cases, gastric ulcer (4% and 11%) and duodenal ulcers (6% and 13%) in the first and second groups, respectively (p < 0.05). HP eradication was achieved in 69.2% of patients in the group with AU and 61.8% of patients with CU, while in 20.5% of patients with CU didn't recur in the year. The influence of HP eradication on the course of allergic urticaria isn't established. In order to achieve stable remission CU by HP eradication in patients with diseases of the digestive tract of prognostically important is the combination of the following factors: the initial elevated levels of antibodies to HP (IgG-AP) in the range of 1:360 to 1:900, serum cytokines: interleukin 1beta in the range (68-22 pg/ml) and TNF alpha (84-50 pg/ml), reduced levels of total IgE from 0 to 38 IU/ml.
  
  
  CONCLUSIONS
  To patients with HP-associated gastrointestinal diseases, combined with idiopathic urticaria is shown holding Helicobacter therapy, because it leads to remission of allergies at 20.5% of patients remaining--to reduce the frequency of exacerbations. To patients with allergic urticaria an HP eradication for the treatment and prevention of AK is not reasonable.
authors.forename: O V
authors.initials: OV
authors.lastname: Sebekina
authors.forename: I E
authors.initials: IE
authors.lastname: Trubitsyna
authors.forename: A A
authors.initials: AA
authors.lastname: Masharova
authors.forename: E N
authors.initials: EN
authors.lastname: D'iakova
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D002908:Chronic Disease; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome; D014581:Urticaria / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007073:Immunoglobulin E